Special Drug Use Surveillance for Adcetris Intravenous Infusion 50 Milligrams Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Hodgkin Lymphoma (Only Pediatric Patients)
Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with relapsed or refractory CD30-positive PTCL or Hodgkin lymphoma (HL) in the actual use of on concomitant Brentuximab Vedotin in routine clinical practice.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Participants with relapsed or refractory lymphoma.
• CD30-positive participants.
• Participants who receive study drug after obtaining approval of CD30-positive PTCL indication of study drug.
Locations
Other Locations
Japan
Takeda Selected Site
Tokyo
Time Frame
Start Date: 2020-02-14
Completion Date: 2023-12-13
Participants
Target number of participants: 95
Treatments
Brentuximab Vedotin 1.8 mg/kg (body weight)
The usual dosage for intravenous administration is 1.8 milligrams per kilograms (mg/kg) (body weight) as Brentuximab Vedotin (genetic recombination) once every three weeks (up to 12 months). The dose may be reduced appropriately according to the participant's condition. Participants receive interventions as part of routine medical care.
Related Therapeutic Areas
Sponsors
Leads: Takeda